NAS:EXAS (USA)
Business Description
Exact Sciences Corp
NAICS : 621511
SIC : 8731
5505 Endeavor Lane, Madison, WI, USA, 53719
Description
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.3 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.76 | |||||
| Debt-to-EBITDA | -4.51 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.7 | |||||
| Beneish M-Score | -2.89 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 40.5 | |||||
| 3-Year EBITDA Growth Rate | -58 | |||||
| 3-Year EPS without NRI Growth Rate | -34.5 | |||||
| 3-Year FCF Growth Rate | 8.1 | |||||
| 3-Year Book Growth Rate | 52.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 15.43 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.94 | |||||
| 9-Day RSI | 32.67 | |||||
| 14-Day RSI | 37.61 | |||||
| 6-1 Month Momentum % | -37.27 | |||||
| 12-1 Month Momentum % | -49.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.48 | |||||
| Quick Ratio | 2.23 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 73.57 | |||||
| Days Sales Outstanding | 40.86 | |||||
| Days Payable | 42.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.48 | |||||
| Operating Margin % | -35.77 | |||||
| Net Margin % | -37.89 | |||||
| ROE % | -21.77 | |||||
| ROA % | -11.13 | |||||
| ROIC % | -12.62 | |||||
| ROC (Joel Greenblatt) % | -96.76 | |||||
| ROCE % | -12.16 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.55 | |||||
| PB Ratio | 2.18 | |||||
| EV-to-EBIT | -11.88 | |||||
| EV-to-Forward-EBIT | -13.5 | |||||
| EV-to-EBITDA | -16.06 | |||||
| EV-to-Forward-EBITDA | -24.45 | |||||
| EV-to-Revenue | 4.5 | |||||
| EV-to-Forward-Revenue | 4.48 | |||||
| EV-to-FCF | -17.61 | |||||
| Price-to-Median-PS-Value | 0.14 | |||||
| Earnings Yield (Greenblatt) % | -8.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:EXAS
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,938.402 | ||
| EPS (TTM) ($) | -4.23 | ||
| Beta | 1.05 | ||
| Volatility % | 34.06 | ||
| 14-Day RSI | 37.61 | ||
| 14-Day ATR ($) | 2.750719 | ||
| 20-Day SMA ($) | 45.286 | ||
| 12-1 Month Momentum % | -49.88 | ||
| 52-Week Range ($) | 35.34 - 108.99 | ||
| Shares Outstanding (Mil) | 176.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exact Sciences Corp Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||